Blackstone Life Sciences and Boston Scientific launch $455 million VITALYST heart pump collaboration
Blackstone Life Sciences announced a $455 million partnership with Boston Scientific to co‑fund development of the VITALYST temporary percutaneous heart pump. The device is aimed at treating acute myocardial infarction cardiogenic shock by increasing cardiac output. Nicholas Galakatos, Global Head of Blackstone Life Sciences, said the collaboration leverages Boston Scientific’s cardiovascular expertise. The deal marks the first time the two companies will jointly fund a Boston Scientific product.
Why it matters
The $455 million investment provides Boston Scientific with substantial non‑dilutive capital to advance a high‑risk device, potentially expanding its product pipeline. For Blackstone Life Sciences, the collaboration adds a large, early‑stage medical‑technology asset to its portfolio, which could generate future returns if the pump reaches market.
Key facts
- 1Blackstone Life Sciences and Boston Scientific agreed to a $455 million collaboration to co‑fund the VITALYST heart pump program. stocktitan.net
- 2The VITALYST system is a temporary percutaneous transvalvular circulatory support device intended to treat acute myocardial infarction cardiogenic shock. stocktitan.net
- 3This is the first co‑funding deal between Boston Scientific and Blackstone Life Sciences for a Boston Scientific product. tipranks.com
- 4Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences, highlighted Boston Scientific’s cardiovascular franchise and the potential of VITALYST to improve efficacy and safety of existing mechanical circulatory support technologies. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.